BIOMAT Database Logo BIOMAT Database Logo

The Importance of Epigenetics in Diagnostics and Treatment of Major Depressive Disorder. 2021

Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Department of Medical Biochemistry, Medical University of Lodz, 92-216 Lodz, Poland.

Recent studies imply that there is a tight association between epigenetics and a molecular mechanism of major depressive disorder (MDD). Epigenetic modifications, i.e., DNA methylation, post-translational histone modification and interference of microRNA (miRNA) or long non-coding RNA (lncRNA), are able to influence the severity of the disease and the outcome of the therapy. This article summarizes the most recent literature data on this topic, i.e., usage of histone deacetylases as therapeutic agents with an antidepressant effect and miRNAs or lncRNAs as markers of depression. Due to the noteworthy potential of the role of epigenetics in MDD diagnostics and therapy, we have gathered the most relevant data in this area.

UI MeSH Term Description Entries

Related Publications

Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Nutrition, Epigenetics, and Major Depressive Disorder: Understanding the Connection.
January 2022, Frontiers in nutrition,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Importance of achieving rapid treatment response in major depressive disorder.
October 2023, CNS spectrums,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
A role for activity-dependent epigenetics in the development and treatment of major depressive disorder.
March 2018, Genes, brain, and behavior,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Gender Differences in Developing Biomarker-Based Major Depressive Disorder Diagnostics.
April 2020, International journal of molecular sciences,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Depressive personality and treatment outcome in major depressive disorder.
June 2010, Journal of personality disorders,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Desvenlafaxine in the treatment of major depressive disorder.
December 2011, Expert opinion on pharmacotherapy,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Desvenlafaxine in the treatment of major depressive disorder.
January 2009, Neuropsychiatric disease and treatment,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Lithium in the treatment of major depressive disorder.
June 2014, Drugs,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Duloxetine in the treatment of major depressive disorder.
April 2007, Neuropsychiatric disease and treatment,
Piotr Czarny, and Katarzyna Białek, and Sylwia Ziółkowska, and Justyna Strycharz, and Gabriela Barszczewska, and Tomasz Sliwinski
Diagnosis and treatment of major depressive disorder.
February 2011, Neurologic clinics,
Copied contents to your clipboard!